Olfactory Training in COVID-19 Associated Loss of Smell

Sponsor
Medical University Innsbruck (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05421221
Collaborator
(none)
100
1
2
17
5.9

Study Details

Study Description

Brief Summary

Olfactory dysfunction (OD) like hyposmia or anosmia has been realized as a common symptom or even cardinal sign of the disease and can be persisting after recovering.

There are two different hypotheses on the pathogenesis of OD in past COVID-19: The central hypothesis, which speculates on neurotrophic abilities on olfactory receptors in the neuroepithelium, and the peripheral hypothesis, which speculates on damage of the sensory olfactory epithelium.

Potential treatment strategies aim for the unique neural plasticity of the olfactory system and its potential for recovery.

Clinical studies and case reports have shown a promising effect of olfactory training (OT) by frequent sniffing and/or exposure to odors 2-4 times a day for several weeks.

The main objective of the study is to assess the effects of olfactory training in patients with COVID-19 related OD on:

  1. objective olfactory testing with the Sniffin' sticks test (identification and discrimination) (primary endpoint),

  2. subjective OD and its impact on the daily life (key secondary endpoint),

  3. other clinical scales and questionnaires referring to OD-related mood and quality of life (other secondary endpoint),

  4. gender differences in COVID-19 related OD (exploratory endpoint). Approach / methods OT will be performed twice a day with a 4-odor training set for 12 weeks. Effects of OT on COVID-19 related OD will be measured with objective and subjective efficacy variables.

The sense of smell is an important function for social relationships and is therefore a challenging clinical problem with few proven therapeutic options.

With this new approach, we want to investigate a possible simple treatment for an impedimental symptom of COVID-19, but also learn more about the pathomechanism of post-infectious OD.

To our knowledge, this will be the first study comparing patients with COVID-19 associated OD with and without OT in clinical outcomes.

Condition or Disease Intervention/Treatment Phase
  • Device: Sniffin' sticks Duftquartett
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Treatment
Official Title:
A Randomized Controlled Trial of the Effectiveness of Olfactory Training on Loss of Smell Related to COVID-19 (SMELL)
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Aug 1, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: olfactory training group

12 weeks of olfactory traiing with Sniffin' sticks "Duftquartett".

Device: Sniffin' sticks Duftquartett
4-odor training set over 12 weeks with Sniffin' sticks "Duftquartett"

No Intervention: no olfactory training with natural history of the disease

natural history of the disease

Outcome Measures

Primary Outcome Measures

  1. primary endpoint [12 weeks]

    change of scores in odor identification and discrimination between baseline and Week 12

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • The subject is aged over 18 years;

  • confirmed diagnosis of COVID-19 at least three months ago (history of positive PCR-testing required);

  • post-infectious COVID-19 related olfactory dysfunction persisting for at least three months with abnormal Sniffin' sticks test (<13/16 items correct in the identification part);

  • the patient is willing to undergo odor training over 12 weeks;

  • written ICF is obtained.

Exclusion Criteria:
  • History of olfactory dysfunction prior to COVID-19 infection due to other conditions e.g. status post traumatic brain injury, Parkinson's disease, allergic rhinitis, etc.;

  • Nasal pathology not related to COVID-19 in the systematic otorhinolaryngological examination including endoscopy.

  • the participant is pregnant

Contacts and Locations

Locations

Site City State Country Postal Code
1 Medical University of Innsbruck Innsbruck Tirol Austria 6020

Sponsors and Collaborators

  • Medical University Innsbruck

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Medical University Innsbruck
ClinicalTrials.gov Identifier:
NCT05421221
Other Study ID Numbers:
  • 12732020
First Posted:
Jun 16, 2022
Last Update Posted:
Jun 16, 2022
Last Verified:
Jun 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 16, 2022